Nam H. Dang, MD, PhD is a board certified medical oncologist with expertise in the study and treatment of lymphoma and chronic lymphocytic leukemia (CLL). Dr Dang's primary research effort emphasizes the development of novel treatment strategies for patients with lymphoma/CLL through the identification of new targets and the utilization of novel targeted therapies. To achieve this aim, he has conducted multiple clinical trials and is active in laboratory research with the goal of translating laboratory findings to the clinical setting for the ultimate benefit of the patient.

Dr. Dang went to Harvard University and Harvard Medical School, where he graduated with top honors, earning his B.A. (magna cum laude), M.D. (magna cum laude), and Ph.D. degrees.

He continued his medical education in the Harvard system with residency training at Massachusetts General Hospital, and fellowship training at Dana-Farber Cancer Institute, becoming board-certified in Internal Medicine and Medical Oncology. Among the several prestigious awards and honors he has garnered include the National Arthritis Foundation Medical Student Award, the Friends Fellowship of Dana-Farber Cancer Institute, the V Foundation Scholar Award, the Howard Hughes Medical Institute Postdoctoral Research Fellowship for Physicians, and the MD Anderson Cancer Center Physician-Scientist Award.

The primary emphasis of the Hunter laboratory is the study of T lymphocyte anergy and tolerance in the context of cancer, infectious diseases, and autoimmune diseases. They are interested in the phenomenon of co-stimulation in T lymphocyte activation, and particularly the immunoregulatory role of the B7:CD28 bimolecular interaction. Funded projects in this area include studies on the modulation of B7 gene expression in macrophages induced by β-1,3 glucans from microbial cell walls, tolerance induction of autoimmune T lymphocytes in collagen-induced arthritis and experimental allergic encephalomyelitis in mice, and co-stimulation and anergy in a mouse tumor model.

Their laboratory is also working with an interdisciplinary team of chemists and biomedical engineers to develop new biosensor technologies for medical diagnosis and new gene microarray technologies for genomics research.

Dr. Lenert is currently an Assistant Professor of Rheumatology at the University of Iowa in the Department of Internal Medicine.

Dr. Lenert attended medical school and did his residency and fellowship at the University of Novi Sad in Yugoslavia. He also attended graduate school in Belgrade, Yugoslavia and received post graduate training at the University of California, San Diego, University of Montreal, Quebec and the University of Iowa.

Dr. Lenert is interested in the study of the mechanisms of CpG-induced receptor binding and downstream signal transduction evens in human and mouse B cells. His clinical interest is in the area of systemic autoimmune diseases.

Dr. Donnica Moore is highly regarded as a women's health expert and advocate. She is founder & President of Sapphire Women’s Health Group and DrDonnica.com, a popular women’s health information website. Best known as “Dr. Donnica”, she has appeared in more than 650 television interviews on health topics. Currently, Dr. Donnica appears weekly on ABC’s “Good Morning America Health” in addition to other frequent guest appearances.

Dr. Moore is a passionate advocate for women’s health issues and medical research in general, but she is particularly committed to advocacy for chronic fatigue syndrome (CFS). This interest was originally motivated by the disproportionate occurrence of CFS/ME in women and too many of these women were treated dismissively or patronizingly by doctors unfamiliar with this condition. Ironically, both her husband and her 16 year old son Brian have since been diagnosed with CFS/ME. Brian has served as the national pediatric spokesperson for the Chronic Fatigue and Immune Deficiency Syndrome (CFIDS) Association and is currently a Youth Trustee for the New Jersey Chronic Fatigue Syndrome Association. Dr. Moore has served as a trustee of the New Jersey Chronic Fatigue Syndrome Association (NJCFSA) and has written several articles about CFS/ME in women and in children. She has also covered CFS/ME in several television & other media interviews as well as in her comprehensive book, Women’s Health for Life (DK 2009)

Dr. Moore is a past member of the editorial boards of the Journal of Women's Health and the Journal of the American Medical Women’s Association (JAMWA). She has been the “Doctor on Call” columnist for First for Women magazine (circ. 1 million) since 2002. She has received more than 30 awards for her achievements in medicine and business including the Women in Government Presidential Achievement Award (2008) for her efforts to raise awareness about cervical cancer prevention; “Woman of the Year” (2002) for the Women’s Health and Counseling Center (Somerset County, NJ); the first “Alumnae Leadership Award” (2001) from Princeton University’s Women’s Center; the New Jersey Commission on the Status of Women’s Connie Woodruff Award (for “the woman who has best demonstrated a major commitment to women’s issues and concerns”); the Soroptomist Woman of Distinction Award (for her continued contributions to women’s health research); and the American Medical Women’s Association Calcium Education Nutrition Award (for the woman physician who has done the most to advance osteoporosis education). Her involvement in organized medicine includes having served on the Board of Directors of the American Medical Women’s Association, the Society for Women's Health Research, and the Friends of the National Institute of Nursing Research. Dr. Moore was a founding member and first co-chair of the American Association of Clinical Endocrinologists Corporate Advisory Board; a member of the Board of Trustees of the National Council on Women's Health; and a member of the Board of Directors of Research!America, a national coalition of over 300 organizations and institutions committed to supporting biomedical research.

Dr. Moore is a cum laude graduate of Princeton University. She earned her medical degree from the State University of New York School of Medicine at Buffalo and undertook residency training in Obstetrics and Gynecology at Temple University. This was followed by additional training in family medicine at Memorial Hospital of Burlington County, NJ. She subsequently spent 7 years as a medical director at Sandoz Pharmaceuticals (now Novartis) in medical affairs, Phase IV clinical research, medical operations, medical education & medical communications.

Dr. Murphy's laboratory is interested in examining issues in bone marrow transplantation (BMT) and its use for the treatment of cancer and other disease states. BMT, both allogeneic and autologous, is currently used for the treatment of a variety of disease states ranging from aplastic anemia to cancer, but significant obstacles limit the efficacy of this procedure–these include marrow graft failure, graft-versus-host disease (GVHD), immune deficiency following the transplant, and, when used for the treatment of cancer, recurrence of the tumor. Natural killer (NK) cells have been demonstrated to be responsible for mediating the specific rejection of bone marrow cell (BMC) allografts in lethally irradiated mice. However, little is known about the nature of these cells and BMC rejection that leads to marrow graft failure. They have found that NK cell subsets exist that are responsible for mediating the specific rejection of BMC from mice bearing the appropriate MHC molecules. In addition, these NK subsets also play an important role in the normal homeostasis of hematopoiesis, suggesting that it is one of their normal physiologic functions. They are currently examining the differentiation of these various subsets. They are also using activated NK cells as a means of providing additional antitumor effects when BMT is used with tumor-bearing mice. They found that adoptive transfer of NK cells can provide significant antitumor effects while at the same time promoting hematopoietic engraftment and preventing GVHD in mice. They are currently examining the mechanism(s) underlying these effects.

Dr. Ware is Head of the Division of Molecular Immunology at LIAI and adjunct Professor of Biology at UC San Diego. Dr. Ware's research focuses on an important group of cytokines produced by white blood cells called tumor necrosis factors (TNF), which control inflammation and host defenses to pathogens. His laboratory is unraveling the molecular mechanisms of how persistent viruses evade immune defenses providing insight into how the immune response is regulated.

Dr. Ware completed his B.S. in 1974 and his PhD in Molecular Biology and Biochemistry in 1979 at the University of California, Irvine. Dr. Ware began his postdoctoral work at the University of Texas Health Science Center in the Department of Biochemistry, and in 1981 he moved to the Dana-Farber Cancer Institute, Boston, Massachusetts, to complete his postdoctoral training. Dr. Ware returned to California as an Assistant Professor of Immunology at University of California, Riverside in 1982, advancing to full professor in 1992. In 1996, Dr. Ware joined the faculty at LIAI as a full Member and Head of the Division of Molecular Immunology.

Dr. Ware serves on several granting agencies and foundations supporting biomedical research including the Arthritis National Research Foundation, the Sandler Program in Asthma Research and the National Institutes of Health. In addition, he serves as Councilor for the International Cytokine Society and is past president of the International Congress on TNF related Cytokines. Dr. Ware is recipient of a National Merit Award from National Institute for Allergy and Infectious Diseases.